PatientsVille.com Logo


Withdrawal Medical Research Studies

Up-to-date List of Withdrawal Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Withdrawal Medical Research Studies

Rank Status Study
1 Recruiting Comparison of Adenoma Detection Miss Rates at Colonoscopy Associated With Different WITHDRAWAL Times
Conditions: Adenoma and/or Adenocarcinoma;   Adenoma
Interventions: Procedure: 3-minute WITHDRAWAL time;   Procedure: 6-minute WITHDRAWAL time
Outcome Measures: Polyp/Adenoma Detection Rate;   Polyp/adenoma Miss Rate
2 Recruiting Dexmedetomidine (Precedex®) for Severe Alcohol WITHDRAWAL Syndrome (AWS) and Alcohol WITHDRAWAL Delirium (AWD)
Conditions: Alcohol WITHDRAWAL Delirium;   Alcohol WITHDRAWAL Associated Autonomic Hyperactivity;   Alcohol WITHDRAWAL Hallucinosis;   Alcohol WITHDRAWAL-Induced Delirium Tremens
Interventions: Drug: Dexmedetomidine;   Drug: Placebo
Outcome Measures: The length of ICU stay defined as the time between randomization and ICU transfer orders.;   The number of delirium-free and ventilator-free days during the first 28 days of hospitalization;   The length in days of the hospital stay;   Scores at hospital discharge on the Mini Mental Exam, Beck Depression Inventory, Beck Anxiety Inventory and PTSD checklist.;   Resource utilization costs associated with this hospitalization.;   Predefined adverse events;   average MINDS score
3 Not yet recruiting Adenoma Detection by Polypectomy During Both Insertion and WITHDRAWAL
Condition: Adenoma of Large Intestine
Interventions: Procedure: Both insertion and WITHDRAWAL;   Procedure: Only WITHDRAWAL
Outcome Measures: Adenoma detection rate;   Number of adenoma per patient
4 Unknown  5HT3 Antagonists to Treat Opioid WITHDRAWAL and to Prevent the Progression of Physical Dependence
Conditions: Opioid WITHDRAWAL;   Physical Dependence
Intervention: Drug: Ondansetron
Outcome Measures: Change in baseline of Objective Opioid WITHDRAWAL Score;   Change in the Baseline of Subjective Opioid WITHDRAWAL Score;   Beck Depression Inventory;   Pain Inventory;   Change in Baseline of Physical Vital Signs;   Serum Factors;   Pain Sensitivity
5 Recruiting The Utility of Timed Segmental WITHDRAWAL During Screening Colonoscopy
Condition: Colonoscopy
Intervention: Procedure: colonoscopy
Outcome Measures: Polyp detection rate (PDR) and Adenoma detection rate (ADR) of patients undergoing a screening colonoscopy either with segmental WITHDRAWAL protocol or with non-segmental WITHDRAWAL protocol.;   The Polyp detection rate( PDR) and Adenoma detection rate (ADR) of patients undergoing screening colonoscopy either with 6-minutes or 8-minutes protocols of the segmental WITHDRAWAL.;   The polyp detection rate( PDR) and Adenoma detection rate (ADR) of patients undergoing screening colonoscopy either with 3-minutes or 4-minutes protocols of the non segmental WITHDRAWAL;   Complication rate
6 Recruiting Efficacy, Safety and Dose-Response Study of Lofexidine in the Treatment of Opioid WITHDRAWAL Followed by Open-Label Lofexidine Treatment
Conditions: Opioid Dependence;   Acute Opioid WITHDRAWAL Syndrome
Interventions: Drug: Lofexidine HCl;   Drug: Lofexidine-matching sugar pill
Outcome Measures: Area under the curve based on Short Opiate WITHDRAWAL Scale (SOWS) scores;   Completion of initial double-blind treatment phase
7 Not yet recruiting Preventing Alcohol WITHDRAWAL Syndrome With Oral Baclofen
Condition: Alcohol WITHDRAWAL Syndrome
Interventions: Drug: Baclofen;   Drug: Placebo
Outcome Measures: Prevention of Progression to Severe Alcohol WITHDRAWAL;   Reduced Severity of alcohol WITHDRAWAL (measured be SEWS score);   Reduced benzodiazepine administration in treatment group
8 Recruiting The Potentially Addictive Properties of Soda: A Feasibility Study
Condition: WITHDRAWAL Symptoms
Intervention: Behavioral: SSB WITHDRAWAL
Outcome Measures: Symptoms of WITHDRAWAL;   Change in diet;   Change in impulsivity;   Change in stress;   Change in preference for soda
9 Not yet recruiting Assessment of Energetic Resonance by Cutaneous Stimulation on WITHDRAWAL Alcohol Symptoms.
Condition: Alcohol WITHDRAWAL Syndrome
Intervention: Other: Energetic Resonance by Cutaneous Stimulation
Outcome Measures: Cushman Score measure after Energetic Resonance by Cutaneous Stimulation;   Anxiety depression scale;   prescribed benzodiazepine amount;   Analogic Visual Scale;   Quality of life scale
10 Recruiting Brain Derived Neurotrophic Factor Serum Levels Evolution During the Six Months After Alcohol WITHDRAWAL
Condition: Alcohol Dependence
Outcome Measures: BDNF serum levels variations between alcohol WITHDRAWAL and 14-, 28- days, 2-, 4- and 6- months after in relation to abstinence at 6 months.;   Search of a correlation between serum BDNF levels and alcohol consumption marker (CDT), GGT, EtG at 28 days 2, 4, and 6 months after alcohol WITHDRAWAL.;   Search of a correlation between serum BDNF levels and the scores to psychometric scales : BDI, MADRS, HAM-A, OCDS, at 28 days 2, 4, and 6 months after alcohol WITHDRAWAL.
11 Unknown  Cardiovascular Consequences of NIV WITHDRAWAL in Patients With Myotonic Dystrophy
Condition: Myotonia
Intervention: Other: WITHDRAWAL of non-invasive ventilation
Outcome Measures: To evaluate endothelial dysfunction (as measured by Peripheral arterial tone (PAT)) and its evolution after four weeks WITHDRAWAL of non-invasive ventilation (NIV).;   To assess arterial stiffness, systemic inflammation (IL6, TNFα, Leptin, CRP), insulin resistance, DHEA, sleep quality, objective and subjective daytime somnolence and their evolution after four weeks WITHDRAWAL of NIV.
12 Recruiting SRL (Sirolimus) WITHDRAWAL
Conditions: Acute Rejection of Liver Transplant;   Effects of Immunosuppressant Therapy
Intervention: Drug: Sirolimus
Outcome Measures: Proportion of tolerant patients off SRL therapy with normal liver biochemistry and graft histology;   Incidence, severity and reversibility of rejection
13 Recruiting A Dietary Supplement for Early Cigarette WITHDRAWAL
Condition: Nicotine Dependence, Cigarettes, With WITHDRAWAL
Interventions: Drug: Dietary Supplement;   Drug: Lactose Placebo
Outcome Measures: Change in the Visual Analog Scale as Compared to Baseline Compared Across Two Conditions;   Potential Side Effects Questionnaire;   Profile of Mood States
14 Unknown  Steroid WITHDRAWAL Immunosuppression After Renal Transplantation
Condition: Disorder Related to Renal Transplantation
Intervention: Drug: Prednisolone
Outcome Measures: the incidence of biopsy-confirmed acute rejection.;   death, graft loss;   adverse events and serious adverse events
15 Recruiting Preventing Alcohol WITHDRAWAL With Oral Baclofen
Conditions: Alcoholism;   Alcohol WITHDRAWAL
Intervention: Drug: Baclofen
Outcome Measures: Alcohol WITHDRAWAL severity as measured on CIWA-AR (Clinical Institute for WITHDRAWAL Assessment) scale;   Total benzodiazepine dose required
16 Unknown  Steroid WITHDRAWAL in Pediatric Renal Transplant Immunosuppression : Impact on Growth, Bone Metabolism and Acute Rejection
Condition: Kidney Diseases
Interventions: Drug: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + WITHDRAWAL Prednisone;   Drug: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone
Outcome Measures: Stimulation of growth after 12 months;   Growth-factors by IGF-I, IGFBP-3 plasma levels Bone metabolism (FA, Ca/Cru, CaxP, 25(OH)VitD, PTH,DXA, pQCT Insulin-sensitivity by ISI method. Molecular markers - acute rejection (FOXP3/IL-17). Acute rejection incidence/protocol renal biopsy
17 Not yet recruiting Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis WITHDRAWAL
Conditions: Cannabis Dependence;   Cannabis Abuse
Intervention: Drug: N-acetylcystein
Outcome Measures: Success rate of WITHDRAWAL defined by a reduction of at least 50% of the rate of urinary carboxy-THC;   The success rate of WITHDRAWAL defined by a declarative reduction of at least 50% of the cannabis;   The retention rate of WITHDRAWAL;   The rate of complete cessation of cannabis use;   Phenotypic profile (3 major types)
18 Recruiting Digoxin WITHDRAWAL in Stable Heart Failure
Condition: Heart Failure
Interventions: Drug: WITHDRAWAL of digoxin;   Drug: Digoxin
Outcome Measures: NYHA Heart Failure class;   6 minute walk test;   Quality of Life;   Change in BNP
19 Recruiting Nicotine WITHDRAWAL Symptoms and Smoking Relapse
Condition: Nicotine Dependence
Outcome Measures: Change in BOLD signal and FC related to task parameters, Behavioral performance, and Self-reported craving, WITHDRAWAL symptoms and mood/affect.;   MRS for glutamate concentration, Plasma ACTH and cortisol, Resting state CBF, ERP and EEG measures, craving and physiological responses to physical drug cues, self-report characterization measures, & amp; structural MRI and DTI data.
20 Recruiting Polypharmacy in the Heart Failure Patient: Are All Prescribed Drug Classes Required? Statin WITHDRAWAL Study
Condition: Heart Failure
Interventions: Drug: WITHDRAWAL of statin therapy;   Drug: Statin therapy
Outcome Measures: NYHA (New York Heart Association) Heart Failure class;   6 minutes walk test;   Quality of life questionnaire;   Change in BNP (Brain natriuretic peptide)

These studies may lead to new treatments and are adding insight into Withdrawal etiology and treatment.

A major focus of Withdrawal research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Withdrawal